Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

ホーム / Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

Back to all Publications

Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6

2016 年 7 月 20 日

Author(s): Alice Ke, Zoe Barter, Karen Rowland-Yeo, Lisa Almond

Year: 2016 年 7 月 20 日

サターラ、バイオシミュレーションを用いたジェネリック医薬品の生物学的同等性のバーチャル評価をさらに前進させるFDA助成金プログラムに採択

プレスリリース

Essentials of Model-informed Drug Development (MIDD) – Top-down vs. Bottom-up Approaches

ブログ (英語)

British Pharmacology Society:
Pharmacology 2021

イベント

Using Simcyp Simulator to Determine DDI Liability of Guanfacine in Children

事例紹介

Powered by Translations.com GlobalLink OneLink Software

サターラ、バイオシミュレーションを用いたジェネリック医薬品の生物学的同等性のバーチャル評価をさらに前進させるFDA助成金プログラムに採択

Essentials of Model-informed Drug Development (MIDD) – Top-down vs. Bottom-up Approaches

British Pharmacology Society:Pharmacology 2021

Using Simcyp Simulator to Determine DDI Liability of Guanfacine in Children

British Pharmacology Society:
Pharmacology 2021